Tectonic Therapeutic (TECX) Competitors $15.62 -1.05 (-6.30%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$15.91 +0.29 (+1.86%) As of 04/4/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TECX vs. INDV, DYN, WVE, SPRY, CALT, EVO, ARDX, OCUL, GPCR, and BGMShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Indivior (INDV), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), ARS Pharmaceuticals (SPRY), Calliditas Therapeutics AB (publ) (CALT), Evotec (EVO), Ardelyx (ARDX), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), and Qilian International Holding Group (BGM). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. Indivior Dyne Therapeutics Wave Life Sciences ARS Pharmaceuticals Calliditas Therapeutics AB (publ) Evotec Ardelyx Ocular Therapeutix Structure Therapeutics Qilian International Holding Group Indivior (NASDAQ:INDV) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Do insiders & institutionals believe in INDV or TECX? 60.3% of Indivior shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor INDV or TECX? In the previous week, Indivior had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Indivior and 0 mentions for Tectonic Therapeutic. Indivior's average media sentiment score of 1.45 beat Tectonic Therapeutic's score of 0.54 indicating that Indivior is being referred to more favorably in the media. Company Overall Sentiment Indivior Positive Tectonic Therapeutic Positive Which has more risk & volatility, INDV or TECX? Indivior has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.71, indicating that its stock price is 171% more volatile than the S&P 500. Do analysts prefer INDV or TECX? Indivior presently has a consensus target price of $15.00, indicating a potential upside of 63.93%. Tectonic Therapeutic has a consensus target price of $77.75, indicating a potential upside of 397.76%. Given Tectonic Therapeutic's higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is INDV or TECX more profitable? Tectonic Therapeutic has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Tectonic Therapeutic's return on equity of -35.53% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Indivior-3.96% -241.73% 15.09% Tectonic Therapeutic N/A -35.53%-31.97% Which has preferable earnings & valuation, INDV or TECX? Tectonic Therapeutic has lower revenue, but higher earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndivior$1.19B1.06$2M-$0.35-26.14Tectonic TherapeuticN/AN/A$12.16M-$6.53-2.39 Does the MarketBeat Community favor INDV or TECX? Indivior received 2 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. CompanyUnderperformOutperformIndiviorOutperform Votes11100.00% Underperform VotesNo VotesTectonic TherapeuticOutperform Votes9100.00% Underperform VotesNo Votes SummaryTectonic Therapeutic beats Indivior on 9 of the 16 factors compared between the two stocks. Remove Ads Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$291.52M$2.83B$5.24B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-2.6529.1621.2017.47Price / SalesN/A420.20356.3585.24Price / CashN/A168.6838.1634.64Price / Book7.333.486.233.79Net Income$12.16M-$72.06M$3.20B$247.10M7 Day Performance-16.25%-12.92%-8.32%-7.32%1 Month Performance-32.47%-20.23%-3.36%-10.20%1 Year PerformanceN/A-34.36%2.72%-7.41% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic2.9033 of 5 stars$15.62-6.3%$77.75+397.8%N/A$291.52MN/A-2.65120INDVIndivior3.3014 of 5 stars$9.53-0.3%$15.00+57.4%-57.3%$1.31B$1.19B-27.231,164Positive NewsGap DownDYNDyne Therapeutics3.0177 of 5 stars$10.46-8.6%$47.46+353.7%-68.7%$1.30BN/A-2.94100Gap DownHigh Trading VolumeWVEWave Life Sciences4.4933 of 5 stars$8.08-6.3%$22.60+179.7%+3.1%$1.24B$108.30M-7.28240High Trading VolumeSPRYARS Pharmaceuticals3.0209 of 5 stars$12.58+0.7%$31.00+146.4%+34.3%$1.23B$89.15M-24.6790Gap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180EVOEvotec1.479 of 5 stars$3.34+0.9%$5.93+77.6%-59.3%$1.18B$777.05M0.004,200Gap DownARDXArdelyx4.131 of 5 stars$4.91-0.4%$10.95+123.0%-36.5%$1.17B$333.62M-30.6990Gap DownOCULOcular Therapeutix3.2301 of 5 stars$7.33-3.3%$16.38+123.4%-24.9%$1.17B$63.72M-5.55230News CoverageGPCRStructure Therapeutics2.0112 of 5 stars$17.31-12.4%$81.29+369.6%-61.5%$1.13BN/A-23.39136News CoverageGap DownBGMQilian International Holding GroupN/A$11.44+0.8%N/AN/A$1.11B$25.10M0.00298Gap Up Remove Ads Related Companies and Tools Related Companies Indivior Competitors Dyne Therapeutics Competitors Wave Life Sciences Competitors ARS Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Evotec Competitors Ardelyx Competitors Ocular Therapeutix Competitors Structure Therapeutics Competitors Qilian International Holding Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TECX Stock Free TECX Stock Alerts